What This Trial Looked At
This 2020 trial in Diabetes, Metabolic Syndrome and Obesity — led by Tyler LeBaron and an international research team — set out to answer a more ambitious question than the early hydrogen-water studies had asked. Could high-concentration hydrogen-rich water, taken consistently for six months, meaningfully shift the cluster of risk factors that defines metabolic syndrome?
The study was a randomised, double-blinded, placebo-controlled trial in 60 adults (30 men, 30 women) diagnosed with metabolic syndrome. After a one-week observation period, participants were randomised to drink either high-concentration hydrogen-rich water (>5.5 millimoles of H₂ per day) or placebo water for 24 weeks. The researchers tracked body composition, blood lipid profile, glucose metabolism, and a panel of inflammation and oxidative-stress biomarkers from baseline to study end.
What They Found
The hydrogen-water group showed significant improvements in core metabolic markers compared with placebo. Total and LDL cholesterol fell. Fasting glucose decreased. HbA1c — the long-term average measure of blood-sugar control — was attenuated. Across these markers the changes pointed in the same direction: less of the lipid and glucose burden that defines metabolic syndrome.
Inflammation and redox biomarkers told a similar story. Markers of systemic inflammation and oxidative stress improved in the hydrogen group, consistent with the underlying mechanism that has motivated hydrogen research from the start: selective neutralisation of the most damaging reactive oxygen species, without disrupting the redox signalling the body depends on for normal function.
Body composition showed a mild but observable shift toward a more favourable profile, including modest reductions in BMI and waist-to-hip ratio in the hydrogen group.
What This Means in Context
This is one of the most methodologically robust human trials of hydrogen-rich water published to date. The 24-week duration is substantially longer than most earlier trials, the design (randomised, double-blind, placebo-controlled) is the gold standard, and the dose used was high — the kind of hydrogen concentration that earlier studies had identified as relevant to outcomes. Metabolic syndrome is a slow-moving cluster of conditions, and a six-month window is long enough to capture meaningful change.
The trial does not prove that hydrogen-rich water can replace established treatments for metabolic syndrome, and the sample of 60 is still modest by the standards of large multicentre cardiovascular trials. What it does establish is that, across a serious panel of clinically meaningful markers, consistent intake of high-concentration hydrogen-rich water produced changes in the direction the underlying mechanism predicted.
What It Means for You
If you live with metabolic syndrome — or are working to reduce the risk factors that lead toward it — this trial adds rigorous evidence that drinking high-concentration hydrogen-rich water over the long term can support the work you are already doing through diet, exercise, and medication. Hydrogen-rich water is not a substitute for established care, and the changes seen in this trial accompanied the participants’ usual daily lives rather than replacing any other intervention. As always, speak with your treating doctor before introducing a new complementary approach.
Citation: LeBaron, T.W., Singh, R.B., Fatima, G., Kartikey, K., Sharma, J.P., Ostojic, S.M., Gvozdjakova, A., Kura, B., Noda, M., Mojto, V., Niaz, M.A., & Slezak, J. (2020). The Effects of 24-Week, High-Concentration Hydrogen-Rich Water on Body Composition, Blood Lipid Profiles and Inflammation Biomarkers in Men and Women with Metabolic Syndrome: A Randomized Controlled Trial. Diabetes, Metabolic Syndrome and Obesity, 13, 889–896. DOI: 10.2147/DMSO.S240122
